Yeah, when these deals come out and the PR never mentions the actual numbers you know it's a token payment of a very small amount.

The bottom line with MNKD is that the company needs a product that has steller clinical trial results and fill a big market for any company to want negotiate with Al. Even then, no guarantee a big pharma will want to partner with Al.

It makes me wonder if Al is going to sidestep big pharma and look to a foreign country or two to finance Afrezza's marketing push after approval.